Resistance to beta-lactams in Gram-negative bacilli: relevance and potential therapeutic alternatives
Rev. esp. quimioter
; 35(supl. 2): 1-15, Sept. 2022. tab, ilus
Article
in English
| IBECS
| ID: ibc-210688
Responsible library:
ES1.1
Localization: ES15.1 - BNCS
ABSTRACT
The indiscriminate and massive antibiotic use in the clinical practice and in agriculture or cattle during the past few decades has produced a serious world health problem that entails high morbidity and mortality the antibiotic multi-drug resistance. In 2017 and 2019, the World Health Organization published a list of urgent threats and priorities in the context of drug resistance, which only included Gram-negative bacteria and specially focused on carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa, as well as carbapenem and third generation cephalosporin-resistant Enterobacteriaceae. This scenario emphasizes the need of developing and testing new antibiotics from different families, such as new beta-lactams, highlighting cefiderocol and its original mechanism of action; new beta-lactamase inhibitors, with vaborbactam or relebactam among others; new quinolones such as delafloxacin, and also omadacycline or eravacycline, as members of the tetracycline family. The present work reviews the importance and impact of Gram-negative bacterial infections and their resistance mechanisms, and analyzes the current therapeutic paradigm as well as the role of new antibiotics with a promising future in the era of multi and pan-drug resistance. (AU)
Full text:
Available
Collection:
National databases
/
Spain
Database:
IBECS
Main subject:
Gram-Negative Bacterial Infections
/
Beta-Lactam Resistance
/
Anti-Bacterial Agents
Limits:
Humans
Language:
English
Journal:
Rev. esp. quimioter
Year:
2022
Document type:
Article
Institution/Affiliation country:
University and Polytechnic Hospital La Fe/Spain